BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 31076405)

  • 1. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
    Jiang H; Liu X; Knolhoff BL; Hegde S; Lee KB; Jiang H; Fields RC; Pachter JA; Lim KH; DeNardo DG
    Gut; 2020 Jan; 69(1):122-132. PubMed ID: 31076405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
    Mohamed AA; Thomsen A; Follo M; Zamboglou C; Bronsert P; Mostafa H; Amen A; Mekawy M; Grosu AL; Brunner TB
    Strahlenther Onkol; 2021 Jan; 197(1):27-38. PubMed ID: 32705304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
    Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
    Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
    Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
    Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
    Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
    Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
    Pathania D; Kuang Y; Sechi M; Neamati N
    Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
    Adamska A; Domenichini A; Capone E; Damiani V; Akkaya BG; Linton KJ; Di Sebastiano P; Chen X; Keeton AB; Ramirez-Alcantara V; Maxuitenko Y; Piazza GA; De Laurenzi V; Sala G; Falasca M
    J Exp Clin Cancer Res; 2019 Aug; 38(1):312. PubMed ID: 31378204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells.
    Nagathihalli NS; Castellanos JA; VanSaun MN; Dai X; Ambrose M; Guo Q; Xiong Y; Merchant NB
    Oncotarget; 2016 Oct; 7(40):65982-65992. PubMed ID: 27602757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
    Zhang J; He DH; Zajac-Kaye M; Hochwald SN
    Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
    Begum A; Ewachiw T; Jung C; Huang A; Norberg KJ; Marchionni L; McMillan R; Penchev V; Rajeshkumar NV; Maitra A; Wood L; Wang C; Wolfgang C; DeJesus-Acosta A; Laheru D; Shapiro IM; Padval M; Pachter JA; Weaver DT; Rasheed ZA; Matsui W
    PLoS One; 2017; 12(7):e0180181. PubMed ID: 28692661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
    Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
    Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.
    Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Gieseler F; Ungefroren H
    Mol Cancer; 2015 Nov; 14():199. PubMed ID: 26588899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
    Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
    Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
    Canel M; Sławińska AD; Lonergan DW; Kallor AA; Upstill-Goddard R; Davidson C; von Kriegsheim A; Biankin AV; Byron A; Alfaro J; Serrels A
    Gut; 2023 Dec; 73(1):131-155. PubMed ID: 36977556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.
    Mace TA; Shakya R; Elnaggar O; Wilson K; Komar HM; Yang J; Pitarresi JR; Young GS; Ostrowski MC; Ludwig T; Bekaii-Saab T; Bloomston M; Lesinski GB
    Oncotarget; 2015 Dec; 6(42):44509-22. PubMed ID: 26575024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.